The article discusses the successful medical treatment of symptomatic vitreomacular adhesion (VMA) with the use of pharmaceutical agent Jetrea or ocriplasmin from ThromboGenics. The advantages mentioned are its convenient administration by in-office intravitreal injection, fewer risks or side effects compared to the vitrectomy procedure and reduced costs to the patient. It also mentioned that the best patient candidates are those with focal areas of adhesion and/or small holes in their retinas.